Our clinical trials are designed to incorporate home visits to limit travel and risk of exposure to COVID-19.
Diabetic Cardiomyopathy (ARISE-HF) Trial:
Contact us at ARISEHF@appliedtherapeutics.com or call 646-809-8110
Applied Therapeutics has completed a Phase 1/2 study of AT-007 in adults (age 18 and older) with Galactosemia. ACTION-Galactosemia evaluated the safety and pharmacokinetics (PK) of AT-007, a central nervous system (CNS) penetrant Aldose Reductase Inhibitor, in healthy volunteers, and explored safety, PK and biomarker effects in adult subjects with Galactosemia. Applied Therapeutics is now conducting a long-term extension with adult study participants.
Applied Therapeutics is currently conducting a pediatric study of AT-007 in children (age 2-17) with Galactosemia. Similar to the ACTION-Galactosemia trial in adults, the pediatric study will evaluate safety, pharmacokinetics, and reduction in the toxic biomarker, galactitol as well as long-term clinical outcomes, such as speech, memory, cognition, behavior, growth and development, and motor skills.
Applied Therapeutics is currently enrolling a registrational clinical trial of AT-007 in people (age 16 and older) with SORD Deficiency. INSPIRE (INhibiting Sorbitol Production through Inhibition of the aldose Reductase Enzyme) is evaluating biomarker efficacy, clinical outcomes and safety in people living with SORD Deficiency treated with AT-007 vs. placebo
Applied Therapeutics is currently enrolling a Phase 3 clinical trial of AT-001 in adults with Type 2 Diabetes for Diabetic Cardiomyopathy (DbCM). ARISE-HF is evaluating whether AT-001 can improve or prevent the decline of functional capacity in patients with DbCM.